Edwards Lifesciences beats Q3 sales estimates, raises full-year sales, adj EPS guidance

Edwards Lifesciences

30/10/2025 20:21

Overview

Edwards Lifesciences Q3 sales grow 14.7% to $1.55 bln, beating analyst expectations

Adjusted EPS for Q3 beats consensus, driven by comprehensive portfolio growth

Company raises full-year sales and adj EPS guidance, reflecting better-than-expected performance

Outlook

Edwards raises 2025 sales growth guidance to high end of 9-10%

Company increases TAVR sales guidance to 7-8% from 6-7%

Edwards lifts 2025 adjusted EPS guidance to $2.56-$2.62

Result Drivers

TAVR SALES - Growth driven by new clinical evidence, updated guidelines, and expanding indications, with stable pricing and competitive position

TMTT GROWTH - Driven by strong adoption of PASCAL and EVOQUE systems, with support from new ESC/EACTS guidelines

EUROPEAN MARKET - Exit of a competitor in Europe contributed modestly to sales growth

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Sales
Beat
$1.55 bln
$1.49 bln (29 Analysts)
Q3 Adjusted EPS
Beat
$0.67
$0.59 (26 Analysts)
Q3 EPS
$0.50


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 21 "strong buy" or "buy", 14 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Edwards Lifesciences Corp is $88.00, about 6% above its October 29 closing price of $82.69

Press Release: ID:nBw44SnKra

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)